Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer

被引：1

作者：

Markowski, Mark C. ^{[1
]}

Pienta, Kenneth J. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA

来源：

ASIAN JOURNAL OF ANDROLOGY | 2015年 / 17卷 / 06期

关键词：

MITOXANTRONE PLUS PREDNISONE; ABIRATERONE ACETATE; INCREASED SURVIVAL; RANDOMIZED-TRIAL; DOUBLE-BLIND; CHEMOTHERAPY; ENZALUTAMIDE; PLACEBO; BONE; IMMUNOTHERAPY;

D O I：

10.4103/1008-682X.150843

中图分类号：

R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

摘要：

Metastatic prostate cancer continues to kill approximately 30,000 men per year. Since 2010, five new therapeutic agents have been Food and Drug Administration (FDA) approved to treat metastatic castration-resistant prostate cancer (mCRPC). With the increasing number of therapies available to clinicians, the most effective sequence in which to implement these treatments remains unknown. The presence or absence of symptoms (i. e., bony pain, visceral crisis) is a key parameter that informs the decision-making process regarding therapy. Treatment algorithms based on: 1) asymptomatic/minimal symptoms, 2) moderate symptoms or chemotherapy ineligible or 3) symptomatic disease need to be developed.

引用

页码：936 / 938

页数：3

共 22 条

[1] AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer [J].

Antonarakis, Emmanuel S. ;

Lu, Changxue ;

Wang, Hao ;

Luber, Brandon ;

Nakazawa, Mary ;

Roeser, Jeffrey C. ;

Chen, Yan ;

Mohammad, Tabrez A. ;

Chen, Yidong ;

Fedor, Helen L. ;

Lotan, Tamara L. ;

Zheng, Qizhi ;

De Marzo, Angelo M. ;

Isaacs, John T. ;

Isaacs, William B. ;

Nadal, Rosa ;

Paller, Channing J. ;

Denmeade, Samuel R. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Luo, Jun .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :1028-1038

[2]

Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095

[3] Bone-Targeting Radiopharmaceuticals Including Radium-223 [J].

Brady, Darren ;

Parker, Chris C. ;

O'Sullivan, Joe M. .

CANCER JOURNAL, 2013, 19 (01) :71-78

[4]

COLLINS C, 1993, J NUCL MED, V34, P1839

[5] Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].

De Bono, Johann S. ;

Logothetis, Christopher J. ;

Molina, Arturo ;

Fizazi, Karim ;

North, Scott ;

Chu, Luis ;

Chi, Kim N. ;

Jones, Robert J. ;

Goodman, Oscar B., Jr. ;

Saad, Fred ;

Staffurth, John N. ;

Mainwaring, Paul ;

Harland, Stephen ;

Flaig, Thomas W. ;

Hutson, Thomas E. ;

Cheng, Tina ;

Patterson, Helen ;

Hainsworth, John D. ;

Ryan, Charles J. ;

Sternberg, Cora N. ;

Ellard, Susan L. ;

Flechon, Aude ;

Saleh, Mansoor ;

Scholz, Mark ;

Efstathiou, Eleni ;

Zivi, Andrea ;

Bianchini, Diletta ;

Loriot, Yohann ;

Chieffo, Nicole ;

Thian Kheoh ;

Haqq, Christopher M. ;

Scher, Howard I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005

[6] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].

de Bono, Johann Sebastian ;

Oudard, Stephane ;

Ozguroglu, Mustafa ;

Hansen, Steinbjorn ;

Machiels, Jean-Pascal ;

Kocak, Ivo ;

Gravis, Gwenaelle ;

Bodrogi, Istvan ;

Mackenzie, Mary J. ;

Shen, Liji ;

Roessner, Martin ;

Gupta, Sunil ;

Sartor, A. Oliver .

LANCET, 2010, 376 (9747) :1147-1154

[7] Prostate cancer as a model for tumour immunotherapy [J].

Drake, Charles G. .

NATURE REVIEWS IMMUNOLOGY, 2010, 10 (08) :580-593

[8] Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study [J].

Fizazi, Karim ;

Carducci, Michael ;

Smith, Matthew ;

Damiao, Ronaldo ;

Brown, Janet ;

Karsh, Lawrence ;

Milecki, Piotr ;

Shore, Neal ;

Rader, Michael ;

Wang, Huei ;

Jiang, Qi ;

Tadros, Sylvia ;

Dansey, Roger ;

Goessl, Carsten .

LANCET, 2011, 377 (9768) :813-822

[9] Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. [J].

Kantoff, Philip W. ;

Higano, Celestia S. ;

Shore, Neal D. ;

Berger, E. Roy ;

Small, Eric J. ;

Penson, David F. ;

Redfern, Charles H. ;

Ferrari, Anna C. ;

Dreicer, Robert ;

Sims, Robert B. ;

Xu, Yi ;

Frohlich, Mark W. ;

Schellhammer, Paul F. ;

Ahmed, T. ;

Amin, A. ;

Arseneau, J. ;

Barth, N. ;

Bernstein, G. ;

Bracken, B. ;

Burch, P. ;

Caggiano, V. ;

Chin, J. ;

Chodak, G. ;

Chu, F. ;

Corman, J. ;

Curti, B. ;

Dawson, N. ;

Deeken, J. F. ;

Dubernet, T. ;

Fishman, M. ;

Flanigan, R. ;

Gailani, F. ;

Garbo, L. ;

Gardner, T. ;

Gelmann, E. ;

George, D. ;

Godfrey, T. ;

Gomella, L. ;

Guerra, M. ;

Hall, S. ;

Hanson, J. ;

Israeli, R. ;

Jancis, E. ;

Jewett, M. A. S. ;

Kassabian, V. ;

Katz, J. ;

Klotz, L. ;

Koeneman, K. ;

Koh, H. ;

Kratzke, R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05) :411-422

[10] A PROSPECTIVE, RANDOMIZED DOUBLE-BLIND CROSSOVER STUDY TO EXAMINE THE EFFICACY OF SR-89 IN PAIN PALLIATION IN PATIENTS WITH ADVANCED PROSTATE-CANCER METASTATIC TO BONE [J].

LEWINGTON, VJ ;

MCEWAN, AJ ;

ACKERY, DM ;

BAYLY, RJ ;

KEELING, DH ;

MACLEOD, PM ;

PORTER, AT ;

ZIVANOVIC, MA .

EUROPEAN JOURNAL OF CANCER, 1991, 27 (08) :954-958

← 1 2 3 →